Biliverdin Reductase (BVR) Peptides That Inhibit PCK-delta for the Potential Treatment of Cancer and Inflammation
Applications:
Dr. M.
Maines is a leading expert in BVR research and has uncovered many applications
for this enzyme. In this invention she has linked BVR to modulation of PKC and
found potent inhibitory peptides that may have utility in both understanding and
treating cancer. A
multiplicity of functions has been ascribed to PKC. Recurring themes are that
PKC is involved in receptor desensitization, in modulating membrane structure
events, in regulating transcription, in mediating immune responses, in
regulating cell growth, and in learning and memory. These functions are achieved
by PKC mediated phosphorylation of other proteins.
Advantages:
This
is the first time BVR and PKCs have been linked and it opens up many avenues for
therapeutic discovery. The peptides will eventually be tested in animals for
anti-cancer activity.
URV Reference Number: 6-1868
Patent Information:
Title |
Country |
Patent No. |
Issued Date |
Use of Human Biliverdin Reductase and Fragments Thereof Protein Kinase C-Delta and ERK Related Conditions |
United States |
9,078,913 |
7/14/2015 |
|
|
|
Inventors:
Keywords:
|